Affibody Archives

News and Trends 8 Mar 2023

Affibody and Chiesi Group to develop treatments for respiratory diseases

Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s proprietary technology. Under the terms of the agreement, the parties will collaborate to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will fund […]

March 8, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Dec 2022

Affibody signs €20 million loan agreement

Affibody Medical AB has received a €20 million ($21.2 million) venture debt loan facility from the European Investment Bank, EIB, backed by the InvestEU program. The investment will support Affibody’s research and development activities in Europe of the next-generation biopharmaceuticals targeting unmet medical needs in the immunology and oncology fields. “We are very pleased and […]

December 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Rallybio announces positive phase 1 results for drug treating PNH and gMG

Affibody’s licensee Rallybio Corporation has announced positive topline results from a phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2020

Swedish Biotech’s Psoriasis Drug Beats Placebo in Phase II

A new class of drug developed by the Swedish biotech company Affibody has proved better at treating symptoms of psoriasis than a placebo in a phase II trial, leading the company to develop the candidate for other conditions such as uveitis and psoriatic arthritis. The phase II study enlisted 108 patients with psoriasis, a chronic […]

June 22, 2020 - 3 minutesmins - By David Wilson

News and Trends 15 May 2020

Affibody Signs €208M Deal To Market Autoimmune Drug in China

Swedish biotech Affibody and Chinese firm Inmagene Biopharmaceuticals will work together to develop and commercialize Affibody’s phase II-stage drug for autoimmune diseases such as psoriasis. Under the agreement, Inmagene will commercialize Affibody’s treatment in the Greater China region and South Korea, as well as develop the drug in the Asia Pacific region excluding Japan. Meanwhile, […]

May 15, 2020 - 3 minutesmins - By Laura Cowen

Expert Advice 5 Nov 2019

How Sweden’s Intellectual Property Law Boosts Biotech Innovation

Founding one biotech company and making a success of it is difficult enough, but Mathias Uhlén has founded 20. Not only is he a successful entrepreneur, he is also a professor at the Royal Institute of Technology in Stockholm and has accumulated more than €135M in research funding during his career. After doing a PhD […]

November 5, 2019 - 10 minutesmins - By Helen Albert

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us